‘Comprehensive’ study by French doctors and scientists does ‘not support’ the use of hydroxychloroquine to treat coronavirus: report

‘Comprehensive’ study by French doctors and scientists does ‘not support’ the use of hydroxychloroquine to treat coronavirus: report
Airmen from the 18th Medical Group conduct COVID-19 testing at Kadena Air Base, Japan, March 20. Under the most current guidance from the Centers for Disease Control, the 18 MDG has increased its testing for the disease. Those who are tested become Persons Under Investigation (PUI), are contacted by Public Health, placed into isolation and instructed on how to avoid spread of their illness to family members in the home. Public Health interviews the PUI and develops a list of “close contacts” who are then called and given instructions to quarantine for 14 days. A close contact is someone who lived with or cared for a PUI, had direct physical contact with a PUI, or shared eating utensils or had prolonged close conversation with a PUI. On average, lab results take 2-5 days to return. If results are negative, isolated and quarantined individuals will be notified and released. If results come back positive, quarantine for the close contact will continue for 14 days and isolation for the PUI will continue until the PUI is medically cleared. Someone who has had contact with someone deemed a close contact does not need to be placed in quarantine but should continue to practice social distancing. (U.S. Air Force photo by Airman 1st Class Mandy Foster)
Alex Henderson
April 15, 2020 | 01:22PM ETNews & Politics

Expert immunologist Dr. Anthony Fauci (who is part of President Donald Trump’s coronavirus task force) and Peter Navarro (one of Trump’s top economic advisers) recently had a heated argument in the White House Situation Room over the benefits of  hydroxychloroquine. Trump and Navarro have been aggressively touting that anti-malaria drug as a possible treatment for coronavirus, while Fauci is much more skeptical and has stressed that a lot more research needs to be conducted. And a new study by French doctors and scientists shows why Fauci remains skeptical: according to the study, hydroxychloroquine might have no benefits at all where COVID-19 is concerned.

The South China Morning Post’s Stephen Chen reports that the French scientists’ research “compared more than 180 patients — some receiving hydroxychloroquine treatment and others who were not treated with the drug — and found their outcomes were almost identical.” The study, according to Chen, was conducted by “doctors and scientists from 12 hospitals and public research institutes across France” and was the “most comprehensive” so far on the possible benefits of hydroxychloroquine as an anti-coronavirus treatment.

The website MedRxiv.org quotes the researchers as saying of the study, “These results do not support the use of hydroxychloroquine in patients hospitalized for documented Sars-CoV-2-positive hypoxic pneumonia.”

The COVID-19 outbreak has turned out to be the deadliest pandemic the world has suffered since the Spanish flu outbreak of 1918. According to researchers at John Hopkins University in Baltimore, COVID-19 had killed more than 129,000 worldwide as of early Wednesday afternoon, April 15. That included at least 26,119 people in the United States (now the coronavirus epicenter), 21,067 in Italy, 18,579 in Spain and 15,729 in France. And because COVID-19 is a new disease, there is no vaccination against it. Health experts have been estimating that a COVID-19 vaccine is at least a year away.

Chen, in his South China Morning Post article, explains why the French study was more “comprehensive” than previous ones.

“They pulled the medical records from four hospitals in France of 181 patients of similar gender, age and health conditions,” Chen observes. “All the patients required oxygen because of lung infections caused by the virus.”

According to the authors of the French study, “In conclusion, we found that hydroxychloroquine did not significantly reduce admission to ICU or death at Day Seven after hospital admission, or acute respiratory distress syndrome in hospitalized patients with hypoxemic pneumonia due to COVID-19. These results are of major importance and do not support the use of hydroxychloroquine in patients hospitalized for a documented Sars-CoV-2 pneumonia.”

Report typos and corrections to: feedback@alternet.org.
{{ post.roar_specific_data.api_data.analytics }}
@2025 - AlterNet Media Inc. All Rights Reserved. - "Poynter" fonts provided by fontsempire.com.